Employees: 01 (2023.0)Legal category: 5485Size: PMECreation date: 2008-03-01 (18 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MOURENX (64150), Pyrenees-Atlantiques
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE RONCEVAUX : revenue, balance sheet and financial ratios
SELARL PHARMACIE RONCEVAUX is a French company
founded 18 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MOURENX (64150),
this company of category PME
shows in 2025 a net income positive of 43 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE RONCEVAUX (SIREN 503314254)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
42 932 €
70 940 €
100 669 €
160 829 €
96 011 €
94 263 €
79 376 €
95 001 €
83 458 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE RONCEVAUX generates positive net income of 43 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 83 k€ -> 43 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
42 932 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 39%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 65%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
38.835%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
64.635%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
108.384
77.199
57.81
40.58
26.683
13.54
0.0
16.664
38.835
Financial autonomy
43.373
50.994
57.403
63.321
69.672
77.163
76.27
75.369
64.635
Repayment capacity
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
38.842025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good+17 pts over 3 years
In 2025, the debt ratio of SELARL PHARMACIE RONCEVAUX (38.84) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
64.64%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good-10 pts over 3 years
In 2025, the financial autonomy of SELARL PHARMACIE RONCEVAUX (64.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 201.12. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
135.603
130.426
97.884
103.858
103.488
136.141
91.514
200.989
201.122
Interest coverage
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
201.122025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Good+39 pts over 3 years
In 2025, the liquidity ratio of SELARL PHARMACIE RONCEVAUX (201.12) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Positioning of SELARL PHARMACIE RONCEVAUX in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE RONCEVAUX is estimated at
681 979 €
(range 462 794€ - 1 070 120€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
462k€681k€1070k€
681 979 €Range: 462 794€ - 1 070 120€
NAF 5 année 2025
Valuation method used
Net Income Multiple
42 932 €
×
15.9x
=681 980 €
Range: 462 795€ - 1 070 120€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE RONCEVAUX with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE RONCEVAUX
What is the revenue of SELARL PHARMACIE RONCEVAUX ?
The revenue of SELARL PHARMACIE RONCEVAUX is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMACIE RONCEVAUX profitable?
Yes, SELARL PHARMACIE RONCEVAUX generated a net profit of 43 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE RONCEVAUX ?
The headquarters of SELARL PHARMACIE RONCEVAUX is located in MOURENX (64150), in the department Pyrenees-Atlantiques.
Where to find the tax return of SELARL PHARMACIE RONCEVAUX ?
The tax return of SELARL PHARMACIE RONCEVAUX is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE RONCEVAUX operate?
SELARL PHARMACIE RONCEVAUX operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart